ATE220549T1 - Verbindungen zur hemmung der ceramid vermittelten signalübertragung - Google Patents

Verbindungen zur hemmung der ceramid vermittelten signalübertragung

Info

Publication number
ATE220549T1
ATE220549T1 AT95944144T AT95944144T ATE220549T1 AT E220549 T1 ATE220549 T1 AT E220549T1 AT 95944144 T AT95944144 T AT 95944144T AT 95944144 T AT95944144 T AT 95944144T AT E220549 T1 ATE220549 T1 AT E220549T1
Authority
AT
Austria
Prior art keywords
compounds
inhibit
vivo
alpha
methods
Prior art date
Application number
AT95944144T
Other languages
English (en)
Inventor
Dennis A Carson
Howard B Cottam
D Bruce Wasson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,551 external-priority patent/US5843943A/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE220549T1 publication Critical patent/ATE220549T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Earth Drilling (AREA)
  • Communication Control (AREA)
  • Steroid Compounds (AREA)
AT95944144T 1994-12-29 1995-12-18 Verbindungen zur hemmung der ceramid vermittelten signalübertragung ATE220549T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36710294A 1994-12-29 1994-12-29
US08/482,551 US5843943A (en) 1994-12-29 1995-06-07 Compounds for inhibition of ceramide-mediated signal transduction
PCT/US1995/016521 WO1996020710A1 (en) 1994-12-29 1995-12-18 Compounds for inhibition of ceramide-mediated signal transduction

Publications (1)

Publication Number Publication Date
ATE220549T1 true ATE220549T1 (de) 2002-08-15

Family

ID=23445942

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95944144T ATE220549T1 (de) 1994-12-29 1995-12-18 Verbindungen zur hemmung der ceramid vermittelten signalübertragung
AT01129223T ATE303994T1 (de) 1994-12-29 1995-12-18 Verbindungen für ceramid-vermittelter signalübertragung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01129223T ATE303994T1 (de) 1994-12-29 1995-12-18 Verbindungen für ceramid-vermittelter signalübertragung

Country Status (7)

Country Link
EP (1) EP0801568B1 (de)
JP (1) JPH11502193A (de)
AT (2) ATE220549T1 (de)
AU (1) AU717243B2 (de)
CA (1) CA2208580A1 (de)
DE (2) DE69534438T2 (de)
WO (1) WO1996020710A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
WO2000000491A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6946465B2 (en) 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
CA2361561A1 (en) * 1999-02-02 2000-08-10 K.U. Leuven Research & Development Immunosurpressive effects of pteridine derivatives
US6930101B1 (en) * 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
IT1307786B1 (it) 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
WO2002024711A1 (fr) * 2000-09-20 2002-03-28 Nikken Chemicals Co., Ltd. Nouveaux composes bicycliques thiazole
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
AU2007286630A1 (en) * 2006-08-23 2008-02-28 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derivatives of uric and thiouric acid for oxidative stress-related diseases
KR20090115953A (ko) * 2007-03-06 2009-11-10 노파르티스 아게 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물
EA035093B1 (ru) 2015-03-04 2020-04-27 Джилид Сайэнс, Инк. 4,6-диаминопиридо[3,2-d]пиримидиновые соединения, модулирующие toll-подобные рецепторы
EP3299371B1 (de) * 2015-05-20 2021-08-25 Guangdong Raynovent Biotech Co., Ltd. Hydroxylpurinverbindungen und verwendung davon
ES2906581T3 (es) 2016-09-02 2022-04-19 Gilead Sciences Inc Compuestos moduladores de los receptores tipo Toll
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573617A1 (de) * 1991-05-24 1993-12-15 Fred Hutchinson Cancer Research Center Modulation der zellulären reaktion auf externe stimuli
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5366978A (en) * 1993-11-03 1994-11-22 Mk Medical Ltd. Treatment for Kawasaki disease

Also Published As

Publication number Publication date
ATE303994T1 (de) 2005-09-15
EP0801568A1 (de) 1997-10-22
DE69527438D1 (de) 2002-08-22
JPH11502193A (ja) 1999-02-23
EP0801568B1 (de) 2002-07-17
AU4601996A (en) 1996-07-24
DE69534438T2 (de) 2006-06-29
WO1996020710A1 (en) 1996-07-11
DE69534438D1 (de) 2005-10-13
CA2208580A1 (en) 1996-07-11
DE69527438T2 (de) 2003-03-06
AU717243B2 (en) 2000-03-23
EP0801568A4 (de) 1998-02-25

Similar Documents

Publication Publication Date Title
ATE300544T1 (de) Verbindungen zur hemmung der ceramid-vermittelten signalübertragung
ATE220549T1 (de) Verbindungen zur hemmung der ceramid vermittelten signalübertragung
EP1193257A3 (de) Verbindungen für Ceramid-vermittelter Signalübertragung
UA29406C2 (uk) Складні ефіри трициклічних аміноспиртів
DK1165558T3 (da) Pyrimido[6,1-a]isoquinolin-4-on-derivater
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
TR199802282T2 (xx) Karbolin t�revleri.
AU2959595A (en) Camptothecin drug combinations and medicaments with reduced side effects
YU48701A (sh) Fenilfenantridini sa dejstvom inhibicije pde-iv
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
SI1147103T1 (en) Phenantrhridine-n-oxides with pde-iv inhibiting activity
DE69333639D1 (en) Trypsininhibitoren
SE9401197D0 (sv) Active compounds
CA2022177A1 (en) Arginine deiminase, its manufacturing method, and an anti-cancer agent containing this enzyme as an effective ingredient
PT1147088E (pt) 6-arilfenantridinas com actividade inibitoria da pde-iv
AU2107700A (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
ES2054904T3 (es) Procedimiento para la preparacion de peptidos con actividad inhibidora de sistemas enzimaticos.
DE69206102D1 (de) Di(2-propyl)ester von 1-fluoro-2-phosphonomethoxy-3-p-toluol-sulfonyloxypropan, deren herstellung und vervendung.
PL350450A1 (en) Vitamin d analogues and their pharmaceutical use
DK1196598T3 (da) DSP-3 phosphatase med dobbelt specificitet
WO2002076397A3 (en) Telomerase inhibitors and methods of their use
SE9901079D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties